[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100602501":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":31,"responsibleParty":47,"collaborators":20,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":20,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":57,"minAge":58,"maxAge":20,"enrollmentInfo":59,"targetDuration":20,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":20,"overallStatus":33,"whyStopped":20,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Birmingham Women's NHS Foundation Trust","OTHER_GOV",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Home antenatal CTG monitoring","EXPERIMENTAL","Participants will be asked to use the remote monitoring devices one a week for a 1 hour each time for up to 6 weeks or until delivery.\n\nParticipants are eligible if they are aged 18 over over, 32+0 gestation onwards, singleton pregnancy, able to speak English and have at least one of 6 high-risk pregnancy conditions.",[13],"Device: Pregnabit Pro device and PregnaOne platform",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","Pregnabit Pro device and PregnaOne platform","Remote CTG device and online dashboard for remote pregnancy care",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Jack Hamer, MBChB","Birmingham Women's and Children's NHS Foundation Trust","PRINCIPAL_INVESTIGATOR",[27],{"name":23,"role":28,"phone":29,"phoneExt":20,"email":30},"CONTACT","0121 472 1377","jack.hamer1@nhs.net",[32],{"facility":24,"status":33,"city":34,"state":20,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"RECRUITING","Birmingham","B152TG","United Kingdom","UK",{"type":39,"coordinates":40},"Point",[41,42],-1.89983,52.48142,{"lat":42,"lon":41},[45],{"name":46,"role":28,"phone":29,"phoneExt":20,"email":30},"Jack Hamer",{"type":25,"investigatorFullName":46,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Clinical research fellow","100602501","remote-cardiotocography-telemonitoring-within-high-risk-pregnancy-care-100602501",false,"NCT07124325","Remote Cardiotocography Telemonitoring Within High-risk Pregnancy Care","The Use of Remote Cardiotocography Telemonitoring Within High-risk Pregnancy Care.","Inclusion Criteria:\n\n* Women aged ≥18 years\n* Gestational age 32+0 weeks onwards.\n* Singleton pregnancy.\n* Able to speak English\n* Receiving antenatal care which includes routine antenatal fetal monitoring for one of the 6 index conditions (hypertensive disease in pregnancy, reduced fetal growth (small for gestational age and fetal growth restriction) obstetric cholestasis, PPROM, previous history of stillbirth and recurrent reduced fetal movements )\n* Able to give written informed consent.\n* Willing to attend hospital immediately in the event of an unexpected finding whilst using the home devices.\n\nExclusion Criteria:\n\n* Multiple pregnancy.\n* Fetal abnormalities or a non-viable fetus.\n* Body mass index (BMI) ≥35\n* Women with internal cardiac devices such as pacemaker and implantable cardioverter defibrillator.\n* History of allergic reaction to skin adhesives and\u002For latex.\n* Acute or chronic skin lesions and wounds in areas in contact with the device.",true,"FEMALE","18 Years",{"count":60,"type":61},50,"ESTIMATED","INTERVENTIONAL",[64],"NA","The overall aim of this research proposal is to explore the feasibility and acceptability of home antenatal maternal-fetal monitoring technology within a high-risk pregnancy group. The investigators hypothesise that home monitoring is feasible and acceptable to both pregnant women and HCPs.\n\n50 women from a single site will be recruited to use a home cardiotocography (CTG) device alongside routine antenatal care. Participants will use this device once a week, for an hour at a time, for up to 6 weeks or until delivery. The primary outcome is 20 minutes of continuous monitoring. Additional outcomes assess acceptability, adherence and safety.",[67,68,69,70,71],"Pregnancy","High Risk","Telemonitoring","Telemedicine","Cardiotocography","2025-08-08",{"date":74,"type":75},"2025-08-15","ACTUAL",{"date":77,"type":75},"2025-06-11",{"date":79,"type":61},"2026-04-01",{"name":5,"class":6},1]